Median Psoriasis Area and Severity Index (PASI) with infliximab treatment at weeks 0, 2, and 6.
(Adapted with permission from Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–42.)